Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7351 - 7375 of 8023 in total
Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Investigational
Matched Description: … Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. …
Etalocib has been used in trials studying the treatment of Pancreatic Cancer, Carcinoma, Non-Small-Cell Lung, and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Matched Description: … Etalocib has been used in trials studying the treatment of Pancreatic Cancer, Carcinoma, Non-Small-Cell …
Pinometostat has been used in trials studying the treatment of Leukemia, Acute Leukemias, Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Acute Lymphocytic Leukemia, among others.
Investigational
Matched Description: … Pinometostat has been used in trials studying the treatment of Leukemia, Acute Leukemias, Acute Myeloid …
Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
Investigational
Matched Description: … Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects …
Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).
Investigational
Matched Description: … Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy …
AZD-8848 is under investigation in clinical trial NCT01818869 (To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects).
Investigational
Matched Description: … clinical trial NCT01818869 (To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of
LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies).
Investigational
Matched Description: … LGH-447 is under investigation in clinical trial NCT02160951 (Dose Escalation Study of LGH447 in Japanese …
PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).
Investigational
Matched Description: … PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for …
TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
Investigational
Matched Description: … investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of
Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Ravoxertinib is under investigation in clinical trial NCT01875705 (A Dose-Escalation Study of GDC-0994 …
CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).
Investigational
Matched Description: … under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of
BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and …
Snubh-nm-333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)).
Investigational
Matched Description: … -333 F-18 is under investigation in clinical trial NCT02149017 (Phase 1 and Phase 2 Clinical Trials of
Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).
Investigational
Matched Description: … Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on …
FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Description: … FF-10101-01 is under investigation in clinical trial NCT03194685 (Study of FF-10101-01 in Patients With …
PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Investigational
Matched Description: … PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau …
IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
Investigational
Matched Description: … IDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid …
Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer).
Investigational
Matched Description: … Avotaciclib is under investigation in clinical trial NCT03579836 (Evaluation of Safety and Efficacy in …
NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled heparin.
Investigational
Matched Description: … an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.
Investigational
Matched Description: … The product is intended for basal insulin treatment of diabetes mellitus. …
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral …
Displaying drugs 7351 - 7375 of 8023 in total